Masimo Corporation - Common Stock (MASI)
Healthcare › Electromedical & Electrotherapeutic Apparatus
Price History
Feb 9, 2026 — May 11, 2026Investment Snapshot
- P/B of 11.84 — trading above book value
- Piotroski F-Score 8/9 — financially strong with improving fundamentals
- Loss-making — negative ROE of -20.6%
- Revenue declining 27% annually
Masimo Corporation - Common Stock (MASI) is a Healthcare company operating in Electromedical & Electrotherapeutic Apparatus, listed on the NASDAQ , with a market capitalisation of $9.3 billion . Key value metrics: P/B ratio 11.84, Piotroski F-Score 8 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Masimo Corporation - Common Stock — Fundamental Analysis Summary
On financial health, MASI shows a strong Piotroski F-Score of 8/9, indicating improving fundamentals across profitability, leverage, and efficiency, and negative return on equity of -20.6% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.57.
StockPik's composite Value Score for MASI is 52/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
MASI reports a high gross margin of 62.5% (sector average: 40.1%) and a solid operating margin of 20.0%.
MASI shows revenue declining at 27% year-over-year, with earnings growing at 50%.